GlassScriptPhysician profile
Helen K Evans
NPI 1972076628
$9,229.93
in general payments reported to CMS, 2019-2025
25 companies · $1,893 in 2025
The $1,893 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,533 · 2022: $1,213 · 2023: $1,198 · 2024: $3,392 · 2025: $1,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,340 · Travel and Lodging: $2,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,340.45 |
| Travel and Lodging | $2,143.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $2,565.29 | 2022-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,460.30 | 2021-2025 | Lifevest |
| Abiomed | $1,134.19 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $901.80 | 2021-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $899.52 | 2021-2024 | Xarelto |
| Pfizer INC. | $427.11 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $378.79 | 2021-2025 | Brilinta, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.74 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $252.93 | 2021-2024 | |
| Boston Scientific Corporation | $203.95 | 2021-2025 | Watchman Flx |
| Merck Sharp & Dohme LLC | $161.75 | 2021-2025 | Verquvo |
| Edwards Lifesciences Corporation | $111.31 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Alnylam Pharmaceuticals INC. | $67.86 | 2022-2025 | Onpattro |
| Amgen INC. | $66.74 | 2021-2024 | Repatha |
| Daiichi Sankyo INC. | $56.00 | 2022-2023 | Injectafer |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $54.78 | 2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $51.37 | 2021-2022 | |
| Cvrx, INC. | $47.41 | 2023 | Barostim Neo System |
| Heartflow, INC. | $31.40 | 2024 | |
| Sanofi-Aventis U.S. LLC | $30.00 | 2024 | |
| Inspire Medical Systems, INC. | $15.73 | 2025 | Inspire |
| Getinge USA Sales, LLC | $15.38 | 2021 | |
| Abbott Laboratories | $14.35 | 2024 | Aveir |
| Regeneron Healthcare Solutions, INC. | $13.94 | 2023 | Evkeeza |
| Medtronic, INC. | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.